Danaher develops technology for the dental, life sciences, diagnostics and environmental markets. The Washington, D.C.-based company will pay $53 per share in cash for Cepheid. Shares of Cepheid jumped almost 52 percent to $52.26 upon news of the acquisition. The stock closed on Friday at $34.42, according to USA Today.
Cepheid creates molecular systems for genetic testing, which help physicians understand an individual’s genetic make-up to make better informed decisions surrounding diagnosis, prognosis and treatment options. The company expects revenue of up to $635 million for 2016.
The acquisition will not only improve Danaher’s operational efficiencies, but also expand margins for the company’s $5 billion diagnostics division, according to Danaher.
More articles on supply chain:
What is the cost of discarding unused surgical supplies?
Treatment for rare degenerative neuromuscular disease earns orphan drug status
FDA designates clot retrieval devices as initial treatment for strokes
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
